Search in:

Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 2

Submit an article Journal homepage

1,113

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Palbociclib for the treatment of postmenopausal breast cancer – an update

Guenther G. StegerDepartment of Internal Medicine I/Division of Oncology, Medical University of Vienna, Vienna, Austria;Comprehensive Cancer Center Vienna, Vienna, AustriaCorrespondence[email protected]

Michael GnantSurgical Department, Medical University of Vienna, Vienna, Austria;Comprehensive Cancer Center Vienna, Vienna, Austria

Rupert BartschDepartment of Internal Medicine I/Division of Oncology, Medical University of Vienna, Vienna, Austria;Comprehensive Cancer Center Vienna, Vienna, Austria

Pages 255-263 | Received 14 Sep 2015, Accepted 11 Dec 2015, Published online: 14 Jan 2016

Cite this article
https://doi.org/10.1517/14656566.2016.1133590
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Perou CM, Sorlie T, Eisen MB. Molecular portraits of human breast tumours. Nature. 2000;406:747–752.
PubMed Web of Science ®Google Scholar
Anderson WF, Rosenberg PS, Petito L, et al. Divergent estrogen receptor-positive and-negative breast cancer trends and etiologic heterogeneity in Denmark. Int J Cancer. 2013;133(9):2201–2206.
PubMed Web of Science ®Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
Web of Science ®Google Scholar
Beslija S, Bonneterre J, Burstein HJ, et al Central European Cooperative Oncology Group (CECOG): Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771–1785.
PubMed Web of Science ®Google Scholar
Bergh J, Jönsson P-E, Lidbrink K, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30:1919–1925.
PubMed Web of Science ®Google Scholar
Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–1670.
PubMed Web of Science ®Google Scholar
Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11(2 Pt 2):865s–70s.
PubMed Web of Science ®Google Scholar

* of importance for understanding mechanisms of endocrine therapy resistance in luminal breast cancer.

Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med. 2012;366:520–529.
PubMed Web of Science ®Google Scholar
Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol. 2012;30(22):2718–2724.
PubMed Web of Science ®Google Scholar
https://clinicaltrials.gov/ct2/results?term=pi3k+breast+cancer+phase+III&Search=Search
Google Scholar
Stone S, Jiang P, Dayananth P, et al. A complex structure and regulation of the P 16 (MTS1) locus. Cancer Res. 1995;55:2988–2994.
PubMed Web of Science ®Google Scholar
Swanton C. Cell-cycle targeted therapies. Lancet Oncol. 2004;5:27–36.
PubMed Web of Science ®Google Scholar
Buckley MF, Sweeney KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene. 1993;8(8):2127–2133.
PubMed Web of Science ®Google Scholar
Lundgren K, Braun M, Pineda S, et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res 2012;14(2):R57.
PubMed Web of Science ®Google Scholar

* of importance for understanding mechanisms of endocrine therapy resistance in luminal breast cancer.

Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
PubMed Web of Science ®Google Scholar

* of importance for understanding the mode of action of the CDK4/6 inhibitor palbociclib in luminal breast cancer.

Bosco EE, Knudsen ES. RB in breast cancer: at the crossroads of tumorigenesis and treatment. Cell Cycle. 2007;6:667–671.
PubMed Web of Science ®Google Scholar
Fry DW, Harvey PJ, Keller P, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.
PubMed Web of Science ®Google Scholar

* of importance for understanding the mode of action of the CDK4/6 inhibitor palbociclib in luminal breast cancer.

Beaver JA, Amiri-Kordestani L, Charlab R, et al. FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2015;21:4760–4766.
PubMed Web of Science ®Google Scholar
Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18:333–345.
PubMed Web of Science ®Google Scholar
Miller TW, Balko JM, Fox EM, et al ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1:338–351.
PubMed Web of Science ®Google Scholar
Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104:1862–1868.
PubMed Web of Science ®Google Scholar
Flaherty KT, LoRusso PM, DeMichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18:568–576.
PubMed Web of Science ®Google Scholar
DeMichele A, Clark AS, Tan KS, et al. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res. 2014;21:995–1001.
PubMed Web of Science ®Google Scholar
Slamon DJ, Hurvitz SA, Applebaum S, et al. Phase I study of PD0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. J Clin Oncol. 2010;28(suppl; abstr 3060):15s.
PubMed Web of Science ®Google Scholar
Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
PubMed Web of Science ®Google Scholar

** of considerable importance: results and interpretation of the randomized phase III study leading to the rapid approval of palbociclib for the treatment of ER-positive, HER2-negative, postmenopausal breast cancer patients with advanced disease.

Turner NC, Ro J, Andre F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015;373:209–219.
PubMed Web of Science ®Google Scholar
Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347:1566–1575.
PubMed Web of Science ®Google Scholar
Mitri Z, Karakas C, Wei C, et al. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. 2015;33:890–894.
PubMed Web of Science ®Google Scholar
Akli S, Zheng PJ, Multani A, et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 2004;64:3198–3208.
PubMed Web of Science ®Google Scholar
Nanos-Webb A, Jabbour NA, Multani AS, et al. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat. 2012;132:575–588.
PubMed Web of Science ®Google Scholar
Berghoff A, Bago-Horvath Z, De Vries C, et al. Brain metastases free survival differs between breast cancer subtypes. Br J Cancer. 2012;106:440–446.
PubMed Web of Science ®Google Scholar
Raub TJ et al. Drug Metab Dispos 2015.[ Epub ahead of print].
Google Scholar
de Gooijer MC et al. Invest New Drugs. 2015. [ Epub ahead of print].
Google Scholar
Gnant M, Steger GG, Bartsch R. CDK4/6 inhibitors in the treatment of luminal breast cancer (comment). Lancet Oncol. 2015;16:2–3.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Palbociclib for the treatment of postmenopausal breast cancer – an update

References

* of importance for understanding mechanisms of endocrine therapy resistance in luminal breast cancer.

* of importance for understanding mechanisms of endocrine therapy resistance in luminal breast cancer.

* of importance for understanding the mode of action of the CDK4/6 inhibitor palbociclib in luminal breast cancer.

* of importance for understanding the mode of action of the CDK4/6 inhibitor palbociclib in luminal breast cancer.

** of considerable importance: results and interpretation of the randomized phase III study leading to the rapid approval of palbociclib for the treatment of ER-positive, HER2-negative, postmenopausal breast cancer patients with advanced disease.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Palbociclib for the treatment of postmenopausal breast cancer – an update

References

* of importance for understanding mechanisms of endocrine therapy resistance in luminal breast cancer.

* of importance for understanding mechanisms of endocrine therapy resistance in luminal breast cancer.

* of importance for understanding the mode of action of the CDK4/6 inhibitor palbociclib in luminal breast cancer.

* of importance for understanding the mode of action of the CDK4/6 inhibitor palbociclib in luminal breast cancer.

** of considerable importance: results and interpretation of the randomized phase III study leading to the rapid approval of palbociclib for the treatment of ER-positive, HER2-negative, postmenopausal breast cancer patients with advanced disease.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date